Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRMD vs OCS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRMD Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–2 Matrix Metrics)

CRMD Overall Winner 6-Pillar Tally: CRMD 6 – 0 OCS Matrix Metrics: CRMD 7 – 2 OCS

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Oculis Holding AG (OCS) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas OCS carries 39.9/100 (SELL) at $7.55 (N/M Forward P/E, -9558.9% operating margin).

  • Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile OCS is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRMD vs OCS
CRMD NASDAQ Head-to-Head Winner
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
TTM Revenue $1.05B
Forward P/E 49.0x
Beta / 30D Vol 1.20β · 107% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.32 · SMA50: $7.11
OCS NASDAQ
Oculis Holding AG Ordinary shares
Pharmaceutical Preparations
$7.55
-1.11% 1D
Market Cap $417.9M
TTM Revenue $937,000
Forward P/E N/M
Beta / 30D Vol 1.14β · 60% Vol
Unified Composite Score
39.9 / 100 SELL
Tech 35.0 Fund 48.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $7.72 · SMA50: $8.65

6-Pillar Scorecard Institutional Category Breakdown (CRMD 6 – 0 OCS)

Columns: Metric · CRMD · OCS
1. Valuation Multiples CRMD
Forward P/E 49.0x N/M
Trailing P/E 2.4x N/M
PEG Ratio 3.79x N/M
EV / Revenue N/M N/M
2. Growth & Scale CRMD
Revenue Growth (YoY) -47.7% -97.1%
Earnings Growth (YoY) +6.7% +0.0%
TTM Revenue (USD) $1.05B $937,000
Market Cap $384.7M $417.9M
3. Profitability & Quality CRMD
Gross Margin 87.4% N/A
Operating Margin 41.0% -9558.9%
Net Profit Margin 15.5% 0.0%
Return on Equity (ROE) 15.3% -47.5%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) $785M -$71M
Cash Flow Margin 74.6% N/A
Net Cash / Leverage $535M Net Cash $64M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRMD
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 56.3% (25th %ile) 51.8% (3rd %ile)
Put/Call OI Skew 0.69x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity 46.4% of Rev ($488M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRMD (7) vs OCS (2)
Institutional Metric CRMD OCS Criterion Row Edge
Market Capitalization
Scale
$384.7M $417.9M Larger Scale OCS
Trailing P/E Ratio
Valuation
2.4x N/M Lower Multiple CRMD
Forward P/E Ratio
Valuation
49.0x N/M Lower Multiple CRMD
Revenue Growth (YoY)
Growth
-47.7% -97.1% Higher Growth CRMD
Operating Margin (TTM)
Profitability
41.0% -9558.9% Higher Margin CRMD
Net Profit Margin
Profitability
15.5% 0.0% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
15.3% -47.5% Higher ROE CRMD
52-Week Range Position
Momentum
3% ($5–$13) 3% ($7–$34) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.20β · 107% Vol 1.14β · 60% Vol Lower Realized Risk OCS
Unified Institutional Score
Composite Signal
53.2 / 100 (HOLD) 39.9 / 100 (SELL) Higher Composite CRMD
Trailing 12M Revenue (USD)
Operating Scale
$1.05B $937,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.79x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$785M ($535M Net Cash) -$71M ($64M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OCS +35.94 pp
CRMD: -32.3% · OCS: +3.64%
3M Horizon CRMD +2.88 pp
CRMD: -39.84% · OCS: -42.72%
6M Horizon CRMD +35.23 pp
CRMD: -37.86% · OCS: -73.09%
1Y Horizon CRMD +4.67 pp
CRMD: -56.16% · OCS: -60.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMD vs OCS. Trailing 12-month operating profitability (CRMD 41.0% vs OCS -9558.9%) and valuation multiples (CRMD 49.0x vs OCS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.05B
Gross Margin87.4%
Op. Margin41.0%
ROE / Fwd P/E15.3% · 49.0x
OCS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$937,000
Gross MarginN/A
Op. Margin-9558.9%
ROE / Fwd P/E-47.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRMD BREAKDOWN
109d in phase · OBV DISTRIBUTION
Current IV 56.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OCS BREAKDOWN
131d in phase · OBV NEUTRAL
Current IV 51.8%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OCS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($488M)
90D Engineering Disclosures 0 Published
OCS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $417.9M market capitalization and -9558.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRMD vs OCS Key Questions & Quantitative Answers

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Oculis Holding AG (OCS) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas OCS carries 39.9/100 (SELL) at $7.55 (N/M Forward P/E, -9558.9% operating margin). Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile OCS is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRMD leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with OCS at -97.1% YoY revenue growth and +0.0% YoY earnings growth on $937,000 TTM revenue (N/A gross margin, -9558.9% operating margin). On trailing 12-month operating scale, CRMD generates $1.05B in USD-normalized revenue versus $937,000 for OCS. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($488M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OCS.

CRMD screens cheaper on headline valuation multiples. CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas OCS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus OCS (-47.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk). By comparison, OCS carries 51.8% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.14β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.